Monica Midha, MD
For patients with advanced CKD, low risk of nephrogenic systemic fibrosis with group II GBCAs
June 9, 2021
What is the risk of nephrogenic systemic fibrosis (NSF) with use of group II gadolinium-based contrast agents (GBCAs) in patients with chronic kidney disease (CKD) stages IV and V?
Hospital acquisition had no significant change in the rate of readmission or mortality
June 8, 2021
How do hospital acquisitions or consolidations affect patient satisfaction, the rate of readmission, and the mortality rate?